Company News

Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology

Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal.  The article, titled “Single-copy detection of somatic variants from solid and liquid biopsy” is freely available online at www.nature.com/articles/s41598-021-85545-3. As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer. Read more

Related stories

Read More

The Park community continues to grow with the arrival of the Internet Watch Foundation (IWF), a global leader in online ...

Read More

Mursla Bio is stepping up its expansion in the United States as it prepares to launch its liver cancer surveillance ...

Read More

Park member Gearset is featured in Business Weekly, with CEO Kevin Boyle reflecting on the company’s journey from startup to ...

Want to see your news featured here? Contact the team and let’s spread the word.